Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging.

Fifty-eight patients suspected of having focal hepatic disease were studied prior to and following the intravenous administration of manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (DPDP), a hepatobiliary magnetic resonance (MR) contrast agent. Four doses (3, 5, 8, or 10 mumol/kg) of Mn-DPDP were used to test the hypothesis that Mn-DPDP-enhanced MR imaging would display enhancement in tumors of hepatocellular origin. A total of 203 lesions were evaluated. Histologic proof was available in 32 cases, and in 26 cases lesions were evaluated on the basis of characteristic imaging findings. Statistical calculations for distinction of tumors of hepatocellular origin yielded a sensitivity of 100%, a specificity of 92.0%, an accuracy of 93.6%, a positive predictive value of 75.9%, and a negative predictive value of 100%. The authors conclude that the presence and patterns of enhancement at Mn-DPDP-enhanced MR imaging permit reliable distinction between hepatocellular and nonhepatocellular tumors.